Attitudes of U.S. Muslims Toward Psychedelics.
Syed F. Rab, Salman S Ahmad, Roman Palitsky, Ali J Zarrabi
Psychedelic Medicine March 1, 2026 DOI: 10.1089/psymed.2024.0044 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 235 |
| Population | Muslims living in the United States |
| Keywords | Muslims Mental health Psychedelic attitudes |
| Citations | 1 |
| Key findings | A weak negative correlation was found between rejection attitudes toward mental health services and acceptance of psychedelic therapies among Muslims living in the United States. |
Abstract
Muslims living in the United States (MLUS) are underrepresented in psychedelics research. Despite growing research on psychedelic-assisted mental health care, little is known about its acceptance among MLUS, a population with some history of rejecting mental health services. This study examined whether MLUS' rejection attitudes toward mental health services were related to lower acceptance of psychedelic therapies. We analyzed survey responses from 235 MLUS. Participants completed measures assessing attitudes toward mental health services and psychedelic therapies. Correlations and t-tests were used to assess the relationship between these attitudes and to examine demographic differences. A weak negative correlation was observed between rejection attitudes toward mental health services and acceptance of psychedelics. Participants demonstrated moderate openness to psychedelics overall. Higher education was associated with more favorable attitudes toward both mental health services and psychedelic therapies. Further research is needed to understand how educational and cultural factors shape these attitudes. Contextualizing MLUS views on psychedelics is essential for advancing equitable and culturally responsive mental health care.
Citations in the library
Cites 14
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Journal of Psychopharmacology August 31, 2016
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine October 1, 2023
- Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature BMC Psychiatry July 31, 2018
- Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment Drugs Education Prevention and Policy April 30, 2021
and 9 more in the library